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Water-soluble fullerenes can be engineered to regulate activation of mast cells (MC) and control 
MC-driven diseases in vivo. To further understand their anti-inflammatory mechanisms a C70-
based fullerene conjugated to four myo-inositol molecules (C70-I) was examined in vitro for its 
effects on the signaling pathways leading to mediator release from human lung MC. The C70-I 
fullerene stabilizes MC and acts synergistically with long-acting β2-adrenergic receptor agonists 
(LABA) to enhance inhibition of MC mediator release through FcεRI-simulation. The inhibition 
was paralleled by the upregulation of dual-specificity phosphatase one (DUSP1) gene and 
protein levels. Concomitantly, increases in MAPK were blunted in C70-I treated cells. The 
increase in DUSP1 expression was due to the ability of C70-I to prevent the ubiquitination and 
degradation of DUSP1. These findings identify a mechanism of how fullerenes inhibit 
inflammatory mediator release from MC and suggest they could potentially be an alternative 
therapy for steroid resistant asthmatics. 
 
From the Clinical Editor: This study investigates the role and mechanism of action of 
fullerenes in deactivating mast cell-based inflammation, paving the way to the development of a 
novel, non-steroid therapy in reactive airway disease. 
 




The use of corticosteroids (also known as glucocorticosteroids, glucocorticoids, or steroids) is 
the hallmark treatment for patients suffering from many chronic inflammatory and immune 
diseases (such as asthma) yet the treatment response is extremely variable among patients. 
Specific subsets of patients are non-responsive to such treatments and are termed steroid 
resistant. These patients often fail to respond to even extremely high dosages of inhaled 
corticosteroids (ICS), therefore much research has been focused on understanding the 
mechanisms of ICS action to better understand non-responsive patients.1 Several different studies 
have found that the dual-specificity phosphatase 1 (DUSP1) is a prospective regulator of this ICS 
response.2, 3, 4, 5, 6 Dual-specificity phosphatase 1 is one in a family of protein phosphatases which 
has been shown in vitro to inactivate mitogen-activated protein kinases (MAPK).7 Upregulation 
of DUSP1 directly results in the de-phosphorylation/inactivation of mitogen-activated protein 
kinase (MAPK) via dephosphorylation of the threonine and/or tyrosine residues and thus acts as 
a regulator through a negative feedback mechanism.8, 9, 10 The induction of the DUSP1 gene and 
subsequent inhibition of MAPKs result in the reduced expression of pro-inflammatory 
cytokines11, 12, 13 
 
While ICS therapy remains a successful first line treatment for persistent cases of asthma, 
consistent use of steroids can have many harmful side effects. In addition, polymorphisms 
in DUSP1 expression are associated with clinical effectiveness of ICS therapy for asthma.5 For 
patients nonresponsive to ICS therapy β2-adrenergic receptor agonists are used. However, the 
link between DUSP1 expression and patient responses to ICS/β2-adrenergic receptor agonists is 
not completely understood. Many cell types respond to steroids by upregulating DUSP1, which 
dephosphorylates and inactivates both MAPK and JNK resulting in significant reductions 
in mediator release and the production of pro-inflammatory cytokines. 
 
Lung mast cells (MC) are effector cells in the asthmatic response14 and release of their asthma-
triggering mediators has been shown to be inhibited by steroids15, 16 and β2-adrenergic receptor 
agonists.17 The role of DUSP1 expression in activated human lung MC following 
pharmacological interventions has not been studied. Clues for a role for DUSP1 in MC-driven 
responses came from studies where MC from knockout mice lacking DUSP1 show enhanced 
degranulation and are highly susceptible to anaphylaxis.18 Mast cell stabilizing nanomaterials 
were also shown to increase DUSP1 gene expression which paralleled inhibition of mediator 
release.19 Based upon these similarities, we investigated the mechanism underlying C70-
Tetrainositol (C70-I) inhibition of lung MC mediator release and compare its effects to those of 
steroids and β2-adrenergic receptor agonists. As shown below C70-I inhibited both FcεRI-
mediated degranulation and GM-CSF cytokine production which was paralleled with increases 
in DUSP1 expression. Furthermore, C70-I synergized with long-acting β2-adrenergic receptor 
agonists (LABA) to potentiate this inhibition. These findings provide mechanistic insight into 
how C70-I can mediate MC degranulation and cytokine production and how DUSP1 
polymorphisms could influence varying responses in patient ICS treatment5 through the 




C70-I synthesis and characterization 
 
The C70-I was synthesized by conjugating four myo-inositol molecules (cis-1,2,3,5-trans-4,6-
cyclohexanehexol) to each C70 carbon cage via Bingel–Hirsch cyclopropanation reaction.20, 21, 22 
C70-I has two inositol moieties at each of the two poles of the oval-shaped C70 molecule. These 
myo-inositol moieties solubilize the C70 molecule in aqueous media. Myo-inositol has been 
shown to significantly reduce inflammation in two widely used animal models for 
inflammation.23 The final compound was characterized using matrix assisted laser desorption 
ionization mass spectrometry (MALDI-MS), nuclear magnetic resonance (1H and 13C NMR), 
high-performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy 
(FTIR), and dynamic light scatter/zeta potential (DLS/ζ). C70-I was found to be approximately 
30 nm in diameter and fully dispersed in buffered saline, it has a molecular formula of 
C100H44O32 with MW of 1756 Da, and a zeta potential of − 16.90 mV (Supplemental Figure 1A). 
Additionally, cell toxicity was assessed by incubation with concentrations shown effective for 
inhibition (10− 8, 10− 7, 10− 6, and 10− 5 M) and viability counts taken on days three, six, and nine. 
No toxicity was observed using trypan blue exclusions compared to control cells (Supplemental 
Figure 1B). Pre-incubation of MC with a fluorophoretagged-C70-I (Texas Red) revealed uptake 
of fullerenes by MC with high efficiency at concentrations down to 10− 10 M after five hours of 




Mast cells were harvested from tissue received by the Cooperative Human Tissue Network and 
cultured using methods previously described.24, 25, 26 Mast cells (> 95%; 1 × 107 cell/condition; 
each condition performed in triplicate) were incubated with or without C70-I (10− 5 M for 16 h; 
37 °C; 6% CO2), washed in fresh warm (37 °C) media and supernatants removed (to remove pre-
formed mediators), and fresh warm medium alone (negative) or medium containing anti-FcεRI 
Abs (1 μg/ml) added for two hours at 37 °C. Cells were centrifuged, the supernatant and the 
pellet immediately frozen and microarray performed using the Human Whole Genome 
OneArray™ gene expression profiling service (Phalanx Biotech Group) report. Microarray 
analysis was performed and analyzed as described previously.19 The UNCG Human Studies 
International Review Board approved all studies. 
 
Immuno-blotting and immuno-precipitation 
 
Mast cells (~ 3.0 × 106 cells/ml) were pretreated with or without C70-I and either cross-linked 
with anti-FcεRI Abs (0.5 μg/ml) or left untreated in a 37 °C incubator with 6% CO2. Cells were 
lysed using methods previously described.24, 25, 26 For immuno-precipitations (IP), lysates were 
pre-cleared with Protein A/G agarose beads, followed by overnight incubation with anti-DUSP1 
(Abcam, Cambridge, MA) conjugated beads at 4 °C and washed extensively to isolate DUSP1 
proteins. Precipitates were subjected to SDS-PAGE (10% SDS gels; Life Technologies, Grand 
Island, NY) and immuno-blotting (IB) as described.24 For highly efficient and quantitative 
exposure, IR700 or IR800-conjugated secondary antibodies were measured using Licor’s Odyssey 
infrared imaging system (Licor Inc. Lincoln, NE). The band intensities were quantified as 
described27 and normalized to the house-keeping gene, β-actin. 
 
Mast cell mediator release 
 
Lung MC of the MCT (tryptase-positive, chymase-negative; predominant type seen in the alveoli 
of the lung > 93%)28 were incubated for 16 h with or without C70-I and ICS alone (at increasing 
dosages to evaluate dose response), or in combination with β2-adrenergic receptor agonists or 
both overnight (16 h; 37 °C; 6% CO2).29 Cells were washed and activated with optimal 
concentrations (0.5 μg/ml) of anti-FcεRI Abs (3B4) for two hours (β-Hex) or 16 h (cytokines) at 
37 °C. Mediator release was measured as described previously.25, 30 Incubation times and 
concentrations were previously optimized and it was determined that 70-carbon fullerenes were 
taken up by MC through an endocytosis-dependent mechanism and persisted in the MC for up to 
one week, predominantly homing to the ER, but also to a lesser degree found in 




Pretreatment of MC with C70-I upregulates DUSP1 gene and protein levels 
 
Microarray analysis was used to obtain a broad overview of those FcεRI-associated signaling 
molecules influenced by C70-I pre-incubation following FcεRI activation.19 Interestingly, C70-I 
caused a dramatic increase in expression of wide range of genes, including several within the 
DUSP family. Notably, DUSP1 increased relative gene expression levels approximately 55% 
compared to cells that were not cross-linked with FcεRI. Cells pre-incubated with C70-I (10− 5 M) 
for 16 h prior to activation increased gene expression to approximately 155% (Figure 1, A). Next, 
a dose response was performed to find the optimal concentration of C70-I that could affect the 
protein expression of DUSP1 in MC. Cells incubated with C70-I at 10− 5 M were found to 
maximally increase DUSP1 protein expression (Figure 1, B). These data were further supported 
by IB of the DUSP1 protein at two, four, and six hours, where the pre-incubation of MC with 
C70-I markedly increased protein expression by nearly 99% at four and six hours (Figure 1, C). 
Therefore, the MC inhibition observed with C70-I was paralleled by significant increases in 
DUSP1 expression. 
 
C70-I upregulation of DUSP1 protein expression modulates activation of MAPK 
 
To further understand the correlation between DUSP1 expression and MC inhibition with C70-I, 
experiments were performed examining DUSP1 downstream targets. Given that increases in 
DUSP1 activity will directly result in reduction of MAPK via de-phosphorylation of 
threonine and/or tyrosine residues, protein analysis of phosphorylated MAPK (p-MAPK) levels 
in C70-I MC pretreated with 10− 5 M (the concentration that maximally activated DUSP1 protein 
expression; Figure 1) was performed. As expected, phosphorylation of MAPK was dramatically 
reduced at the four and six hour time points (Figure 2, A); the same time points that showed 
significant increase in DUSP1 expression (Figure 1, C). At six hours phosphorylation of MAPK 
was nearly 80% lower in cells treated with C70-I as opposed to those that remained untreated 
(Figure 2, B) indicating the C70-I-induced upregulation of DUSP1 directly results in de-
phosphorylation of MAPK in MC. These results suggest that increases in DUSP1 from C70-I 
directly prevent phosphorylation of MAPK which is crucial for MC activation leading to 
mediator release. 
 
To delineate the possible mechanism of action that C70-I inhibits phosphorylation of MAPK and 
subsequent cell activation, activated cells were subjected to immuno-precipitation (IP) with anti-
DUSP1 antibody, followed by immuno-blotting (IB) with anti-ubiquiton (Ub), anti-phospo-
MAPK, or anti-β-Actin. In FcεRI-crosslinked cells DUSP1 protein was highly ubiquitinated 
(Figure 2, C; compare lane one vs. lane two) which provides for a negative feedback mechanism 
for inhibition in other cell types.31 However, when pre-incubated with C70-I there was a dramatic 
reduction in DUSP1 ubiquitination (Figure 2, C; lane 3). These data indicate that the increased 
DUSP1 levels (and subsequent decrease in MAPK levels) in cells pre-incubated with C70-I are 




Figure 1. Mast cell pretreatment with C70-I increases DUSP1 gene and DUSP1 protein expression. Fullerene (C70-I 
[10− 5 M) treated and untreated MC were challenged with (XL) or without (−) anti-FcεRI (1 μg/ml) for two hours. 
Cell pellets from each condition in triplicates were used for RNA isolation and gene microarray as described. Gene 
microarray data conduction by Phalynx Biotechnology (A)demonstrates the increases in mean relative intensities of 
DUSP1 gene expression increases in C70-I pretreated samples (P < 0.005; ± SD of six observed values). To evaluate 
dose responses of C70-I (B), MC were pretreated with C70-I (10− 8-10− 5 M) and lysed as described. The lysates were 
immuno-blotted with polyclonal rabbit-anti-DUSP1 antibodies (1 μg/ml) and probed on the Odyssey infrared 
imaging system with anti-rabbit IR800 secondary antibodies (results typical in three separate immuno-blots). Relative 
pixel intensity (green bar graph) of the IR800 protein band expression of DUSP1 was quantified and normalized 
(Licor Odyssey imaging software) to the house-keeping gene, β-Actin to ensure equal protein levels were loaded 
into each lane (red band). To evaluate time course effects of C70-I (C), MC were cross-linked with (XL) or without 
(−) anti-FcεRI (1 μg/ml) for two, four, or six hours and immuno-blotted as described in (B). 
 
 
Figure 2. Mast cell pretreatment with C70-I decreases phosphorylation of MAPK1. Mast cells were pretreated with 
or without C70-I (10− 5 M), washed, and challenged with (XL) or without (−) anti-FcεRI (1 μg/ml) for two, four, or 
six hours. Lysates were immuno-blotted with polyclonal rabbit-anti-phospho-MAPK1 antibodies (1 μg/ml) and 
probed on the Odyssey infrared imaging system with anti-rabbit IR800secondary antibodies (A). Relative pixel 
intensity of the IR800 phospho-MAPK1 protein band (green band and bar graph) and IR700 house-keeping gene, β-
Actin (red band and bar graph) was quantified. Percent reduction of MAPK1 in untreated MC and C70-I pretreated 
MC was normalized to the house-keeping gene and pixel density of was calculated (B). Results are typical of three 
separate immuno-blots. In (C) cells were immuno-precipitated with anti-DUSP1 antibodies, run on SDS-PAGE, and 
blotted with the indicated antibodies. 
 
C70-I and corticosteroids inhibit FcεRI-mediated-MC degranulation 
 
Inhaled corticosteroids can also inhibit MC mediator release, but certain asthmatic patients are 
less responsive to ICS, due potentially to DUSP1 polymorphisms. Thus, based on the results 
suggesting a DUSP1-dependent inhibition of lung MC using C70-I, several commonly used ICS 
were compared in their ability to inhibit FcεRI-mediator release. A battery of ICS was initially 
evaluated (data not shown) and revealed that fluticasone and budesonide had the most significant 
impact on blunting mediator release from MC, therefore comparative studies were conducted on 
these two specific ICS. C70-I (10− 7-10− 5 M) and fluticasone or budesonide ICS (10− 6 and 
10− 5 M) were capable of significantly reducing MC degranulation without affecting cell viability 
(> 95% using trypan blue exclusion) compared to their untreated counterparts (Table 1). Optimal 
inhibition was observed with 10− 5 M pretreatments of fluticasone, budesonide, and C70-I 
resulting in inhibitions of 55%, 48%, and 68% respectively. Higher doses did not increase 
inhibition and resulted in some loss in cellular viability. These data demonstrate that C70-I is 
capable and comparable to ICS mono-therapy in preventing human lung MC FcεRI-mediated 
degranulation. 
 
Table 1. Mean % FcεRI-mediated degranulation in C70-I or ICS (fluticasone or budesonide) 
treated and untreated lung MC. 
Treatment/[Conc; M] Release β-Hex (%) ± S.E. (%) Inhibition β-Hex ± S.E. 
Spontaneous 4.7 ± 0.4 
 
Positive Control 56.9 ± 4.7 
 
Fluticasone [8] 52.7 ± 3.7 7% ± 6.8% 
Fluticasone [7] 42.3 ± 2.2 26% ± 5.1% 
Fluticasone [6]⁎ 34.9 ± 2.3 39% ± 4.0% 
Fluticasone [5] ⁎  25.6 ± 0.5 55% ± 1.2% 
Budesonide [8] 56.6 ± 3.8 1% ± 8.0% 
Budesonide [7] 41.8 ± 3.5 27% ± 7.6% 
Budesonide [6] ⁎  35.6 ± 1.9 37% ± 3.4% 
Budesonide [5] ⁎  29.6 ± 2.9 48% ± 4.2% 
C70-I [8] 53.7 ± 2.1 6% ± 3.9% 
C70-I [7] ⁎  34.4 ± 1.4 40% ± 4.1% 
C70-I [6] ⁎  24.5 ± 3.6 57% ± 7.2% 
C70-I [5] ⁎⁎  18.2 ± 1.5 68% ± 4.1% 
Data shown are mean ± standard error (S.E.) of β-Hex release and percent inhibition of β-Hex release compared to 
untreated, activated MC. Results are representative of three different experiments in triplicates. 
ICS: Inhaled corticosteroid; MC: Mast Cell; M: Molar. 
* P < 0.05. 
** P < 0.005. 
 
Co-incubation of C70-I or corticosteroids with long-acting β2-adrenergic receptor agonists 
inhibits FcεRI-mediated-MC degranulation 
 
Combination techniques of ICS and LABA are commonly used by physicians to treat patients 
suffering from persistent asthma. Given the ability of C70-I to inhibit MC inflammatory mediator 
release through a DUSP1 mechanism and that patient responses to ICS are mediated by DUSP1 
the next aim was to investigate the ability of C70-I to synergize with the LABA. Several LABA 
were investigated at different concentrations, the most efficient inhibitor LABA inhibitor, 
salmeterol, was selected for synergistic studies. As anticipated, MC treated with C70-I or ICS 
combined with LABA (dual-agent approach) revealed increased inhibition of degranulation 
compared to the single-agent approach. A side-by-side comparison of C70-I and LABA or ICS 
and LABA combinatory incubation with MC is illustrated in Table 2. The dual treatment 
response resulted in optimal inhibition of degranulation at concentrations of 10− 5 M fluticasone, 
budesonide, or C70-I co-incubated with 10− 5 M salmeterol with statistically significant 
inhibitions of 59%, 57%, and 75% respectively, on average an increased inhibition of cellular 
degranulation by 7% compared to the single-agent approach. Figure 3 represents a comparison of 
the single-agent (either ICS or C70-I alone) and dual-agent (ICS and LABA or C70-I and LABA) 
approach validating C70-I as a potential alternative to traditional ICS approaches for asthma 
therapy aimed at reducing lung MC hyper-reactivity. In addition, these data illustrate both 
compounds’ synergistic abilities with the LABA salmeterol to prevent FcεRI-mediated lung MC 
degranulation. Although, statistical evaluation of the single-agent versus dual-agent approach did 
not approach significance, it was observed that inhibition was improved in most cases when MC 
were treated synergistically with LABAs and/or fullerenes/ICS. However, the evaluation 
fullerenes and LABA against ICS (fluticasone or budesonide) and LABA at a concentration of 
10− 7 M produced statistically significant results (¥; in Figure 3), indicating that the fullerene 
molecule may be useful in blunting degranulation with similar efficiency to ICS. 
 
Table 2. Synergistic effects on % FcεRI-mediated degranulation in fullerene (C70-I) and LABA 
(salmeterol) or ICS (fluticasone or budesonide) and LABA (salmeterol) treated and untreated 
MC. 
Treatment/[Conc; M] Release β-Hex (%) ± S.E. (%) Inhibition β-Hex ± S.E. 
Spontaneous 6.5 ± 0.5 
 
Positive Control 35.9 ± 3.1 
 
Fluticasone [8]/Salmeterol [5] 35.7 ± 0.6 1% ± 1.4% 
Fluticasone [7]/Salmeterol [5] 26.8 ± 1.5 26% ± 4.2% 
Fluticasone [6]/Salmeterol [5] ⁎   18.1 ± 1.2 50% ± 3.1% 
Fluticasone [5]/Salmeterol [5] ⁎   14.8 ± 2.9 59% ± 5.1% 
Budesonide [8]/Salmeterol [5] 37.8 ± 1.8 No Effect 
Budesonide [7]/Salmeterol [5] 30.3 ± 3.5 16% ± 5.5% 
Budesonide [6]/Salmeterol [5] ⁎   19.4 ± 1.5 46% ± 2.9% 
Budesonide [5]/Salmeterol [5] ⁎   15.4 ± 2.7 57% ± 4.2% 
C70-I [8]/Salmeterol [5] 34.0 ± 0.8 6% ± 1.2% 
C70-I [7]/Salmeterol [5] ⁎   15.9 ± 2.0 56% ± 4.6% 
C70-I [6]/Salmeterol [5] ⁎⁎   13.8 ± 1.4 62% ± 2.7% 
C70-I [5]/Salmeterol [5] ⁎⁎ 9.0 ± 1.3 75% ± 4.0% 
Data shown are mean ± standard error (S.E.) of β-Hex release and percent inhibition of β-Hex release compared to 
untreated, activated MC. Results are representative of three different experiments in triplicates. 
ICS: Inhaled corticosteroid; MC: Mast Cell; M: Molar. 
* P < 0.05. 
** P < 0.005. 
 
C70-I and corticosteroids inhibit FcεRI-mediated-MC GM-CSF cytokine production 
 
Mast cells produce GM-CSF in response to inflammatory stimuli; it is observed that ICS therapy 
can suppress the release of inflammatory mediators.1 Therefore, the ability of C70-I and ICS to 
reduce lung MC FcεRI-mediated-GM-CSF release was investigated. C70-I/ICS were evaluated 
separately and in conjunction with a LABA. As expected, ICS pre-incubation resulted in a dose 
dependent, statistically significant reduction in mediator release when compared to untreated 
controls (Figure 4, A). Pre-incubation with C70-I at increasing doses resulted in greater inhibition 
of mediator release than observed in ICS treatments at similar concentrations (Figure 4, A). The 
synergistic effect of ICS/C70-I co-incubation with LABA resulted in greater inhibition of GM-
CSF production (Figure 4, B), just as observed in the degranulation assays. A comparison of the 
single-agent and dual-agent approach is depicted in Figure 4, C demonstrating that C70-I has 
similar GM-CSF suppressive abilities as traditional ICS, as well as an ability to synergize with 
LABA to further inhibit cytokine production. Albeit, as was observed in the degranulation 
studies statistical significance was not revealed when comparing the single-agent and dual-agent 
therapies, it was found that lower concentrations of C70-I (10− 8 and 10− 7 M) with or without 
LABAs produced statistically significant inhibition when compared to the equivalent ICS (with 
or without LABA) treatment (¥, Figure 4, C). 
 
 
Figure 3. The effects of MC pretreatment with C70-I/ICS individually or in combination with LABA on 
degranulation. MC were cultured with C70-I, fluticasone, or budesonide (10− 8-10− 5 M) or C70-I, fluticasone, or 
budesonide at (10− 8-10− 5 M;) in combination with salmeterol (10− 5 M); each pretreatment condition as well as 
untreated MC controls (Spontaneous and Positive) was challenged with (XL) or without (−) anti-FcεRI (1 μg/ml) for 
30 min at 37 °C and supernatants were collected to measure degranulation as described in previously.24 All studies 
were performed using at least three separate MC donor cultures in triplicates. Statistical significance indicated with 
* (P < 0.05) and ** (P < 0.01) using the Student’s t test to compare respective treatment to untreated positive 
(FcεRI) controls. Statistical significance indicated with ¥ (P < 0.05) using the Student’s t test to compare efficacy 
ICS versus fullerene treatment at respective concentrations. 
 
 
Figure 4. The effects of MC pretreatment with C70-I/ICS individually or in combination with LABA on GM-
CSF cytokine production. MC were cultured with C70-I, fluticasone, or budesonide at (10− 8-10− 5 M) (A) or C70-I, 
fluticasone, or budesonide at (10− 8-10− 5 M) in combination with salmeterol (10− 5 M) (B); each pretreatment 
condition as well as untreated MC controls (Spontaneous and Positive) was challenged with (XL) or without (−) 
anti-FcεRI (1 μg/ml) for 30 min at 37 °C and supernatants were collected to measure mediator release as described. 
Values are presented as total mediator release ng/ml and are representative of three experiments analyzed in 
triplicate. Percent inhibition of GM-CSF production of fullerene/ICS alone (white bar) and fullerene/ICS in 
combination with LABA is displayed in (C) Statistical significance indicated with * (P < 0.05) and ** (P < 0.01) 
using the Student’s t test to compare respective treatment to untreated positive (FcεRI) controls. Statistical 
significance indicated with ¥ (P < 0.05) using the Student’s t test to compare efficacy of ICS 




Inhaled corticosteroids are regarded as the hallmark treatment for patients suffering from asthma. 
Their beneficial effect has been shown to be due in part to the inhibition of pro-inflammatory 
genes. Mast cells play a key role in IgE-dependent inflammatory diseases such as asthma. In 
many cases, MC mediate both the sustained and immediate inflammatory responses 
via degranulation and production of cytokines. Stimulation through the IgE-receptor, FcεRI, 
results in the activation of MAPK and subsequently induces degranulation of 
preformed inflammatory mediators. The role that ICS play in modulating MC activation is of 
much interest, yet a defined understanding of the inhibitory mechanism of ICS at the cellular 
level has not been established. However, one protein, DUSP1, has been given significant 
attention.1, 6, 11 Here it is shown that C70-I upregulates the DUSP1 gene in human lung MC 
resulting in higher protein levels and lower MAPK activation through an ubiquitination pathway. 
Furthermore, combinatory treatments of ICS and LABA can further inhibit MC activation and 
similar inhibition was observed when pre-treating with C70-I, instead of ICS. 
 
Part of the impetus for these studies was the often unpredictable and varied side effects of ICS in 
asthma patients32 as well as the donor variability in the benefit of ICS in some patients.5 This has 
led to efforts to separate the desired anti-inflammatory effects of ICS33 and better understand the 
link between DUSP1 polymorphisms and their link between asthma lung function. Our studies 
have demonstrated that fullerenes are not toxic in vitro or in vivo19, 22, 34, 35, 36, 37, 38, 39 but instead 
have an overall anti-inflammatory effect. Additionally, fullerene uptake is not receptor mediated, 
however it is endocytosed by the cell.29 Given that this anti-inflammatory effect is now 
demonstrated in human lung MC, both alone and in synergy with LABA, they may provide an 
alternative to ICS for patients that are steroid resistant without the unwanted side effects 
observed in high-dosage therapies. It is established the anti-inflammatory actions of ICS are 
known to modulate gene expression via the glucocorticoid receptor (GR).11 Side effects of ICS 
are commonly attributed to gene induction by ligand-activated GRs.11 While the ICS treatment 
strategy is deemed an extremely potent anti-inflammatory therapy, their use often comes with 
some reticence from physicians due to the range and severity of their side effects. Furthermore, it 
has been shown that mutated GRs have failed to activate the ICS response in a subset of 
patients.11 Consequently, the non-receptor mediated mechanism of fullerenes may kinetically 
favor therapeutic intervention in cases of patients that fail to respond adequately or inversely to 
traditional ICS treatment regimes. Additionally, the differences in mechanisms between C70-I 
and ICS, although still in need of further investigation, may be advantageous for a C70-I-inspired 
therapy through a decrease in ICS-associated side effects. 
 
As a protein tyrosine phosphatase, DUSP1 is known to modulate immune responses. 
Specifically, DUSP1 is considered an ICS-induced phosphatase that is capable of 
inhibiting phosphorylation of MAPK in MC as first identified by Kassel et al.40 Furthermore, 
clinical effectiveness of ICS in patients with DUSP1 polymorphisms can be variable, suggesting 
that new therapies should be examined to help better control disease progression.5 The C70-I was 
capable of increasing both gene expression and protein levels of the inhibitory regulator DUSP1, 
just as in ICS therapies. Pre-incubation of FcεRI challenged MC with C70-I resulted in greater 
than a 50% upregulation of DUSP1 gene expression when compared to those untreated, which 
was analogous to high levels of DUSP1 protein expression in challenged MC at early (4 and 6 h) 
time-points. As expected, the upregulation of DUSP1 caused significant (greater than 65%) 
reductions in MAPK activation at these same time-points, suggesting that C70-I could function 
similarly to ICS intervention in modulating MC responses to stimuli. 
 
The gene and protein expression results led to examination of commonly used in vitro functional 
assays to compare two ICS, fluticasone and budesonide, to C70-I as a possible alternative to 
traditional asthma-ICS regulated therapy. Being that both compounds were capable of mediating 
the phosphatase DUSP1, we sought to discover if C70-I could be a successful candidate for 
modulating MC-degranulation and cytokine production. Specifically, optimal doses of all three 
interventions, fluticasone, budesonide, and C70-I result in significant inhibitions of degranulation 
by 55%, 48%, and 68% respectively, with fullerenes being nearly 20% more effective than 
traditional ICS treatments. These results were paralleled in GM-CSF cytokine production, where 
optimal concentrations of fluticasone and budesonide inhibit release by 63% and 57% 
respectively, the same concentration of C70-I revealed nearly 30% greater inhibitions with 
significant reductions in cytokine production by 78%. In light of the degranulation and cytokine 
release assays, fullerenes may be an alternative to traditional ICS treatment. Overall, the 
fullerene intervention was capable of providing statistically significant reductions in MC-
mediator release when compared to ICS treatment at the lower concentrations evaluated 
(10− 7 M). In situations of persistent asthma, patients are often given a dual-therapy of ICS and 
LABA. Therefore, it was considered important to evaluate the ability of C70-I to synergize with 
LABA. Consequently, these strategies mirrored those commonly observed in combinatory 
therapies of ICS/LABA. Such that C70-I co-incubation with the LABA, salmeterol, resulted in 
increased inhibitions compared to fullerene mono-therapy. The synergistic effects were similar to 
those in the ICS/LABA dual-therapeutic strategy, fluticasone/salmeterol, or 
budesonide/salmeterol, while not statistically significant, repeatedly revealed enhanced inhibition 
of degranulation between 4% and 10% respectively when compared to the mono-therapeutic 
approaches. C70-I combinatory therapies with salmeterol resulted in nearly a 10% increase in 
inhibition of degranulation compared to C70-I alone. These same trends were observed in 
cytokine production. Taken together, each of these results provides a heretofore undiscovered 
mechanism for controlling asthma using novel water-soluble fullerenes that are functionally 
similar to the present first-line treatment method, ICS. 
 
Further studies will be required to understand how C70-I functions to increase DUSP1 levels 
after pretreatment; however it is proposed that C70-I offers some protective qualities that prevent 
DUSP1 ubiquitination and subsequent activation-induced degradation. Following MC-activation, 
untreated cells displayed a rapid increase in DUSP1 production, a production that diminishes 
nearly 95% after two hours and 100% after four hours. However, the duration of this spike in 
production persists significantly longer in C70-I treated MC as displayed in Figure 1, C. It is 
proposed that C70-I can prevent proteolysis degradation of the phosphatase, allowing it to act on 
MAPK well into six hours after stimulation with FcεRI. Our efforts are now focused on 
understanding what C70-I interacts with directly or if it is indirectly reducing ubiquitination 
through another mechanism, possibly reduced oxidative stress as has been demonstrated in other 
cell types.41 
 
In conclusion, these studies reveal that strategically functionalized fullerene nanomaterials, like 
ICS, can control human lung MC mediator release through a DUSP1-mediated mechanism. 
However, unlike ICS, their efficacy is not mediated through the glucocorticoid receptor. Since 
the fullerenes are taken up by MC via endocytosis, this may prove beneficial in patients with 
receptor mutations, who subsequently fail to respond to ICS treatment. These findings show that 
using water-soluble fullerenes with side-chain moieties such as C70-I could be pursued as a non-
steroidal based therapy for patients that fail to respond clinically or respond adversely to ICS 
treatment. Additionally, these findings may not only provide a more robust controller therapy 
for patients with asthma, but a therapy with reduced adverse effects commonly associated with 
ICS treatment. 
 
Appendix A. Supplementary data 
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